Investigating a new RNA treatment for heart issues in Duchenne muscular dystrophy
Official title: Targeting myocardial fibrosis with a novel noncoding RNA in Duchenne muscular dystrophy
Funded at Cedars-Sinai Medical Center · NIH-11009962 · Data updated 2026-11-12
This study is looking at a new treatment using a special type of RNA called TY4, which comes from tiny particles in the body, to help reduce heart scarring in people with Duchenne muscular dystrophy (DMD), and it’s taken by mouth along with a protein from breast milk to make it easier for patients to use.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cedars-Sinai Medical Center NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | January 12, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $482,762 |
| NIH project number | 5R01HL167921-02 |
| Project ID | NIH-11009962 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Duchenne muscular dystrophy, particularly those experiencing cardiac issues.
✕Less likely to help
Patients without Duchenne muscular dystrophy or those not experiencing cardiac complications may not benefit from this research.
What this research studies
This research explores the effects of a novel noncoding RNA called TY4, which is derived from extracellular vesicles, on reducing myocardial fibrosis in patients with Duchenne muscular dystrophy (DMD). The study focuses on how TY4 can modify disease progression by targeting macrophages and inducing beneficial changes at the molecular level. The treatment is administered orally, combined with a protein found in breast milk, making it a potentially accessible option for patients. The research aims to establish a new class of RNA drugs that could provide significant therapeutic benefits.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that reduces heart complications in patients with Duchenne muscular dystrophy.
How similar studies have gone: While the approach of using noncoding RNAs is relatively novel, other RNA-based therapies have shown success in treating various conditions, indicating potential for this new class of treatment.
Where this research is happening
-
Cedars-Sinai Medical Center
Los Angeles, United States Active
Researchers
- Principal investigator: Rogers, Russell — Cedars-Sinai Medical Center
- Study coordinator: Rogers, Russell
Related research
Other NIH-funded projects on the same topics.
-
A new RNA treatment to reduce heart scarring in Duchenne muscular dystrophy
A new RNA-based medicine aims to reduce heart scarring in people with Duchenne muscular dystrophy.
-
Advancing manufacturing and release testing for a Duchenne gene editing therapy
A project to optimize how a dual-vector AAV gene editing treatment for Duchenne muscular dystrophy is made and tested, so it can move toward clinical use.
-
Understanding why Duchenne Muscular Dystrophy worsens and how to stop it
A research team at USC is studying Duchenne muscular dystrophy to find out why the disease continues to progress and how to interrupt harmful changes in muscle tissue.
-
Stopping steroid-related muscle and bone wasting in Duchenne muscular dystrophy
Researchers are testing ways to protect muscles and bones in people with Duchenne muscular dystrophy who take long-term steroid medicines.
-
MR clues to how nNOS affects energy use and blood flow in Becker and Duchenne muscular dystrophy
This project looks at how advanced MRI tests can track muscle energy and blood flow changes in people with Becker and Duchenne muscular dystrophy as new gene therapies are explored.
-
Digital motor-skill tracking for infants with Duchenne Muscular Dystrophy using wearables
A wearable-sensor project aims to quietly track and quantify how motor skills develop in babies and young boys with Duchenne Muscular Dystrophy.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.